{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:28:46Z","timestamp":1793039326597,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T00:00:00Z","timestamp":1433548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12016-015-8490-y","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T07:56:37Z","timestamp":1433490997000},"page":"84-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Off-Label Uses of Omalizumab"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4837-782X","authenticated-orcid":false,"given":"David","family":"El-Qutob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,6]]},"reference":[{"issue":"165","key":"8490_CR1","first-page":"1661","volume":"4","author":"K Blondon","year":"2008","unstructured":"Blondon K, Desmeules J, Vogt-Ferrier N, Besson M, Kondo-Oestreicher M, Dayer P (2008) Off-label prescribing. Rev Med Suisse 4(165):1661\u20135, La prescription \u201coff-label\u201d","journal-title":"Rev. Med. Suisse"},{"issue":"9","key":"8490_CR2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"DC Radley","year":"2006","unstructured":"Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166(9):1021\u20136","journal-title":"Arch Intern Med"},{"issue":"5","key":"8490_CR3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jama.2012.207972","volume":"309","author":"AS Kesselheim","year":"2013","unstructured":"Kesselheim AS, Mello MM, Avorn J (2013) FDA regulation of off-label drug promotion under attack. JAMA 309(5):445\u20136","journal-title":"JAMA"},{"issue":"1\u20132","key":"8490_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000234742","volume":"88","author":"B Baird","year":"1989","unstructured":"Baird B, Shopes RJ, Oi VT, Erickson J, Kane P, Holowka D (1989) Interaction of IgE with its high-affinity receptor structural basis and requirements for effective cross-linking. Int Arch Allergy Appl Immunol 88(1\u20132):23\u20138","journal-title":"Int. Arch. Allergy Appl. Immunol"},{"issue":"5","key":"8490_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/ACI.0000000000000096","volume":"14","author":"MP Makris","year":"2014","unstructured":"Makris MP, Papadavid E, Zuberbier T (2014) The use of biologicals in cutaneous allergies\u2014present and future. Curr Opin Allergy Clin Immunol 14(5):409\u201316","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"8490_CR6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.aller.2011.02.003","volume":"39","author":"S Khan","year":"2011","unstructured":"Khan S, Deacock S (2011) Expanding indications of omalizumab therapy in the absence of specific IgE. Allerg Immunol (Madr) 39(3):189","journal-title":"Allerg. Immunol (Madr)"},{"issue":"1","key":"8490_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1939-4551-7-17","volume":"7","author":"ST Holgate","year":"2014","unstructured":"Holgate ST (2014) New strategies with anti-IgE in allergic diseases. World Allergy Organ J 7(1):17","journal-title":"World Allergy Organ. J"},{"issue":"5","key":"8490_CR8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1517\/14712598.2013.782391","volume":"13","author":"KS Babu","year":"2013","unstructured":"Babu KS, Polosa R, Morjaria JB (2013) Anti-IgE\u2013emerging opportunities for omalizumab. Expert Opin Biol Ther 13(5):765\u201377","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"8490_CR9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00228-014-1746-2","volume":"70","author":"I Danes","year":"2014","unstructured":"Danes I, Agusti A, Vallano A, Alerany C, Martinez J, Bosch JA et al (2014) Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol 70(11):1385\u201393","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"8490_CR10","first-page":"1683","volume":"61","author":"J Hirashima","year":"2012","unstructured":"Hirashima J, Hojo M, Iikura M, Hiraishi Y, Nakamichi S, Sugiyama H et al (2012) A case of an asthma patient receiving omalizumab during pregnancy. Arerugi 61(11):1683\u20137","journal-title":"Arerugi"},{"issue":"2","key":"8490_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5114\/pdia.2014.40975","volume":"31","author":"I Kuprys-Lipinska","year":"2014","unstructured":"Kuprys-Lipinska I, Tworek D, Kuna P (2014) Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy dermatologii i alergologii 31(2):104\u20137","journal-title":"Postepy dermatologii i alergologii"},{"key":"8490_CR12","doi-asserted-by":"crossref","unstructured":"Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Jr., Chen H, Carrigan G, et al. (2014) The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J Allergy Clin Immunol","DOI":"10.1016\/j.jaci.2014.08.025"},{"issue":"10","key":"8490_CR13","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2006.01172.x","volume":"61","author":"SG Johansson","year":"2006","unstructured":"Johansson SG, Oman H, Nopp A, Pettersson S (2006) The importance of IgE antibody levels in anti-IgE treatment. Allergy 61(10):1216\u20139","journal-title":"Allergy"},{"issue":"1","key":"8490_CR14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000260086","volume":"152","author":"J Ankerst","year":"2010","unstructured":"Ankerst J, Nopp A, Johansson SG, Adedoyin J, Oman H (2010) Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 152(1):71\u20134","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"8490_CR15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.anai.2013.04.011","volume":"110","author":"DJ Maselli","year":"2013","unstructured":"Maselli DJ, Singh H, Diaz J, Peters JI (2013) Efficacy of omalizumab in asthmatic patients with IgE levels above 700\u00a0IU\/mL: a retrospective study. Ann Allergy Asthma Immunol 110(6):457\u201361","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8490_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/IJGM.S45259","volume":"7","author":"C Vennera Mdel","year":"2014","unstructured":"Vennera Mdel C, Picado C (2014) Novel diagnostic approaches and biological therapeutics for intrinsic asthma. Int J General Med 7:365\u201371","journal-title":"Int J General Med"},{"issue":"3","key":"8490_CR17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/02770903.2012.757780","volume":"50","author":"LP Llano de","year":"2013","unstructured":"de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderias L, Pellicer C et al (2013) Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 50(3):296\u2013301","journal-title":"J Asthma"},{"issue":"2","key":"8490_CR18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","volume":"144","author":"G Garcia","year":"2013","unstructured":"Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et al (2013) A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144(2):411\u20139","journal-title":"Chest"},{"issue":"1","key":"8490_CR19","first-page":"45","volume":"27","author":"C Domingo","year":"2013","unstructured":"Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM (2013) Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents 27(1):45\u201353","journal-title":"J Biol Regul Homeost Agents"},{"issue":"Suppl 3","key":"8490_CR20","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","volume":"37","author":"DA Stevens","year":"2003","unstructured":"Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA et al (2003) Allergic bronchopulmonary Aspergillosis in cystic fibrosis\u2013state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 37(Suppl 3):S225\u201364","journal-title":"Clin Infect Dis"},{"key":"8490_CR21","doi-asserted-by":"crossref","unstructured":"Knutsen AP, Slavin RG. (2011) Allergic Bronchopulmonary Aspergillosis in Asthma and Cystic Fibrosis. Clinical and Developmental Immunology","DOI":"10.1155\/2011\/843763"},{"issue":"4","key":"8490_CR22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0091-6749(88)91034-2","volume":"81","author":"PA Greenberger","year":"1988","unstructured":"Greenberger PA, Patterson R (1988) Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 81(4):646\u201350","journal-title":"J Allergy Clin Immunol"},{"issue":"1 Pt 1","key":"8490_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0091-6749(84)90482-2","volume":"73","author":"P Laufer","year":"1984","unstructured":"Laufer P, Fink JN, Bruns WT, Unger GF, Kalbfleisch JH, Greenberger PA et al (1984) Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 73(1 Pt 1):44\u20138","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"8490_CR24","first-page":"1839","volume":"18","author":"AM Zicari","year":"2014","unstructured":"Zicari AM, Celani C, De Castro G, Valerio De Biase R, Duse M (2014) Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis. Eur Rev Med Pharmacol Sci 18(13):1839\u201341","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"issue":"5","key":"8490_CR25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ppul.22937","volume":"49","author":"K Tanou","year":"2014","unstructured":"Tanou K, Zintzaras E, Kaditis AG (2014) Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 49(5):503\u20137","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"8490_CR26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","volume":"62","author":"CK Ent van der","year":"2007","unstructured":"van der Ent CK, Hoekstra H, Rijkers GT (2007) Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62(3):276\u20137","journal-title":"Thorax"},{"issue":"5","key":"8490_CR27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1753465814547517","volume":"8","author":"S Lehmann","year":"2014","unstructured":"Lehmann S, Pfannenstiel C, Friedrichs F, Kroger K, Wagner N, Tenbrock K (2014) Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 8(5):141\u20139","journal-title":"Ther Adv Respir Dis"},{"key":"8490_CR28","first-page":"CD010288","volume":"9","author":"KR Jat","year":"2013","unstructured":"Jat KR, Walia DK, Khairwa A (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 9:CD010288","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"8490_CR29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","volume":"66","author":"I Tillie-Leblond","year":"2011","unstructured":"Tillie-Leblond I, Germaud P, Leroyer C, Tetu L, Girard F, Devouassoux G et al (2011) Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66(9):1254\u20136","journal-title":"Allergy"},{"issue":"6","key":"8490_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","volume":"66","author":"LA Perez-de-Llano","year":"2011","unstructured":"Perez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O et al (2011) Effects of omalizumab in aspergillus-associated airway disease. Thorax 66(6):539\u201340","journal-title":"Thorax"},{"issue":"2","key":"8490_CR31","first-page":"145","volume":"22","author":"I Sastre","year":"2012","unstructured":"Sastre I, Blanco J, Mata H, Garcia F (2012) A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 22(2):145\u20137","journal-title":"J Investig Allergol Clin Immunol"},{"key":"8490_CR32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/JAA.S34579","volume":"5","author":"J Collins","year":"2012","unstructured":"Collins J, Devos G, Hudes G, Rosenstreich D (2012) Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma and Allergy 5:65\u201370","journal-title":"J Asthma and Allergy"},{"key":"8490_CR33","unstructured":"Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M. (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis. Journal of microbiology, immunology, and infection\u2009=\u2009Wei mian yu gan ran za zhi"},{"issue":"5","key":"8490_CR34","first-page":"416","volume":"19","author":"D Gonzalez de Olano","year":"2009","unstructured":"Gonzalez de Olano D, Gonzalez-Mancebo E, Gandolfo Cano M, Melendez Baltanas A, Valeri-Busto V, Maracionero MA et al (2009) Successful treatment of allergic bronchopulmonary candidiasis with a recombinant anti-immunoglobulin E antibody. J Investig Allergol Clin Immunol 19(5):416\u20137","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"8490_CR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaip.2013.08.014","volume":"2","author":"BL Wolf","year":"2014","unstructured":"Wolf BL, Johnson A (2014) Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab. J Allergy Clin Immunol Prac 2(1):111\u20133","journal-title":"J Allergy Clin Immunol Prac"},{"issue":"1","key":"8490_CR36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/187221312798889257","volume":"6","author":"LD El-Qutob","year":"2012","unstructured":"El-Qutob LD (2012) New methods of prevention and treatment of allergic diseases. Recent Patents Inflamm Allergy Drug Discov 6(1):46\u201364","journal-title":"Recent Patents Inflamm Allergy Drug Discov"},{"issue":"1","key":"8490_CR37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1517\/14656566.2014.860445","volume":"15","author":"E Ridolo","year":"2014","unstructured":"Ridolo E, Montagni M, Melli V, Braido F, Incorvaia C, Canonica GW (2014) Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 15(1):73\u201383","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"8490_CR38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14712598.2013.795943","volume":"13","author":"P Vashisht","year":"2013","unstructured":"Vashisht P, Casale T (2013) Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 13(6):933\u201345","journal-title":"Expert Opin Biol Ther"},{"key":"8490_CR39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2147\/TCRM.S40232","volume":"10","author":"C Lenk","year":"2014","unstructured":"Lenk C, Duttge G (2014) Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 10:537\u201346","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"8490_CR40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","volume":"109","author":"J Kuehr","year":"2002","unstructured":"Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109(2):274\u201380","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8490_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","volume":"39","author":"MV Kopp","year":"2009","unstructured":"Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al (2009) Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 39(2):271\u20139","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"8490_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2332\/allergolint.R-08-164","volume":"57","author":"K Okubo","year":"2008","unstructured":"Okubo K, Nagakura T (2008) Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update. Allergol Int 57(3):205\u20139","journal-title":"Allergol Int"},{"issue":"3","key":"8490_CR43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000199719","volume":"149","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T (2009) Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 149(3):239\u201345","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"8490_CR44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","volume":"21","author":"R Penn","year":"2007","unstructured":"Penn R, Mikula S (2007) The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 21(4):428\u201332","journal-title":"Am J Rhinol"},{"issue":"2","key":"8490_CR45","first-page":"158","volume":"19","author":"M Guglielmo","year":"2009","unstructured":"Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F (2009) Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab. J Investig Allergol Clin Immunol 19(2):158\u20139","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"8490_CR46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2007.09.036","volume":"121","author":"SA Grundmann","year":"2008","unstructured":"Grundmann SA, Hemfort PB, Luger TA, Brehler R (2008) Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 121(1):257\u20138","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"8490_CR47","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/thx.2010.152835","volume":"66","author":"C Vennera Mdel","year":"2011","unstructured":"Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M (2011) Efficacy of omalizumab in the treatment of nasal polyps. Thorax 66(9):824\u20135","journal-title":"Thorax"},{"issue":"5","key":"8490_CR48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","volume":"110","author":"T Tajiri","year":"2013","unstructured":"Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K et al (2013) Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 110(5):387\u20138","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"8490_CR49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110\u20136","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8490_CR50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhin09.144","volume":"48","author":"JM Pinto","year":"2010","unstructured":"Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318\u201324","journal-title":"Rhinology"},{"issue":"8","key":"8490_CR51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al (1990) The American college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094\u2013100","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8490_CR52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaci.2007.10.040","volume":"121","author":"AM Ruppert","year":"2008","unstructured":"Ruppert AM, Averous G, Stanciu D, Deroide N, Riehm S, Poindron V et al (2008) Development of churg-strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 121(1):253\u20134","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8490_CR53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1378\/chest.108.2.320","volume":"108","author":"A Churg","year":"1995","unstructured":"Churg A, Brallas M, Cronin SR, Churg J (1995) Formes frustes of churg-strauss syndrome. Chest 108(2):320\u20133","journal-title":"Chest"},{"issue":"12","key":"8490_CR54","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMc061914","volume":"355","author":"DE Winchester","year":"2006","unstructured":"Winchester DE, Jacob A, Murphy T (2006) Omalizumab for asthma. N Engl J Med 355(12):1281\u20132","journal-title":"N Engl J Med"},{"issue":"2","key":"8490_CR55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/02770900701767704","volume":"45","author":"E Bargagli","year":"2008","unstructured":"Bargagli E, Madioni C, Olivieri C, Penza F, Rottoli P (2008) Churg-strauss vasculitis in a patient treated with omalizumab. J Asthma 45(2):115\u20136","journal-title":"J Asthma"},{"issue":"2","key":"8490_CR56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.08-2990","volume":"136","author":"ME Wechsler","year":"2009","unstructured":"Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L (2009) Churg-strauss syndrome in patients treated with omalizumab. Chest 136(2):507\u201318","journal-title":"Chest"},{"issue":"6","key":"8490_CR57","first-page":"226","volume":"46","author":"A Graziani","year":"2014","unstructured":"Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF (2014) Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis a case report. Eur Ann Allergy Clin Immunol 46(6):226\u20138","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"8","key":"8490_CR58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/thx.2006.076513","volume":"63","author":"S Pabst","year":"2008","unstructured":"Pabst S, Tiyerili V, Grohe C (2008) Apparent response to anti-IgE therapy in two patients with refractory \u201cforme fruste\u201d of Churg-Strauss syndrome. Thorax 63(8):747\u20138","journal-title":"Thorax"},{"issue":"3","key":"8490_CR59","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1002\/ppul.22884","volume":"49","author":"E Iglesias","year":"2014","unstructured":"Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Lirola Cruz MJ, Falcon Neyra MD, Salazar Quero JC et al (2014) Successful management of churg-strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49(3):E78\u201381","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"8490_CR60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000103228","volume":"144","author":"P Giavina-Bianchi","year":"2007","unstructured":"Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J (2007) Administration of anti-IgE to a churg-strauss syndrome patient. Int Arch Allergy Immunol 144(2):155\u20138","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"8490_CR61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2009.05.023","volume":"124","author":"MF Spina","year":"2009","unstructured":"Spina MF, Miadonna A (2009) Role of omalizumab and steroids in churg-strauss syndrome. J Allergy Clin Immunol 124(3):600\u20131","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8490_CR62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.11-1881","volume":"142","author":"H Kaya","year":"2012","unstructured":"Kaya H, Gumus S, Ucar E, Aydogan M, Musabak U, Tozkoparan E et al (2012) Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 142(2):513\u20136","journal-title":"Chest"},{"issue":"1","key":"8490_CR63","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1378\/chest.12-2035","volume":"143","author":"C Domingo","year":"2013","unstructured":"Domingo C, Pomares X (2013) Can omalizumab be effective in chronic eosinophilic pneumonia? Chest 143(1):274","journal-title":"Chest"},{"issue":"6","key":"8490_CR64","first-page":"439","volume":"22","author":"C Barnig","year":"2012","unstructured":"Barnig C, Hilger C, Muti D, Blaumeiser M, Purohit A, Hentges F et al (2012) Anaphylaxis to vapors of roasting chicken controlled by omalizumab. J Investig Allergol Clin Immunol 22(6):439\u201340","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"8490_CR65","first-page":"490","volume":"18","author":"A Perez Pimiento","year":"2008","unstructured":"Perez Pimiento A, Bueso Fernandez A, Garcia Loria J, Rodriguez Cabreros MI, Mosquera MR, Garcia CA (2008) Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 18(6):490\u20131","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"8490_CR66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1398-9995.2008.01702.x","volume":"63","author":"M Olivieri","year":"2008","unstructured":"Olivieri M, Biscardo CA, Turri S, Perbellini L (2008) Omalizumab in persistent severe bakers\u2019 asthma. Allergy 63(6):790\u20131","journal-title":"Allergy"},{"issue":"6","key":"8490_CR67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/all.12149","volume":"68","author":"F Lavaud","year":"2013","unstructured":"Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R et al (2013) Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 68(6):813\u20135","journal-title":"Allergy"},{"issue":"2","key":"8490_CR68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1398-9995.2006.01310.x","volume":"62","author":"R Brown","year":"2007","unstructured":"Brown R, Turk F, Dale P, Bousquet J (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62(2):149\u201353","journal-title":"Allergy"},{"issue":"2","key":"8490_CR69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5415\/apallergy.2014.4.2.129","volume":"4","author":"AB Ozturk","year":"2014","unstructured":"Ozturk AB, Kocaturk E (2014) Omalizumab in recurring larynx angioedema: a case report. Asia Pacific Allergy 4(2):129\u201330","journal-title":"Asia Pacific Allergy"},{"key":"8490_CR70","unstructured":"Baker R. (1998) FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 8\u20139"},{"issue":"2","key":"8490_CR71","first-page":"295","volume":"12","author":"J O\u2019Reilly","year":"2003","unstructured":"O\u2019Reilly J, Dalal A (2003) Off-label or out of bounds? prescriber and marketer liability for unapproved uses of FDA-approved drugs. Annals Health Law \/ Loyola Univ Chicago, School Law Ins Health Law 12(2):295\u2013324, table of contents","journal-title":"Annals Health Law \/ Loyola Univ Chicago, School Law Ins Health Law"},{"issue":"9000","key":"8490_CR72","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(96)91182-4","volume":"347","author":"S Turner","year":"1996","unstructured":"Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of \u201coff-label\u201d and unlicensed drugs in paediatric intensive care unit. Lancet 347(9000):549\u201350","journal-title":"Lancet"},{"issue":"2","key":"8490_CR73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2005.02.014","volume":"53","author":"RA Krathen","year":"2005","unstructured":"Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53(2):338\u201340","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8490_CR74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2005.09.030","volume":"54","author":"JE Lane","year":"2006","unstructured":"Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68\u201372","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8490_CR75","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2005.12.045","volume":"55","author":"PG Vigo","year":"2006","unstructured":"Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168\u201370","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"8490_CR76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jaci.2007.08.060","volume":"120","author":"B Belloni","year":"2007","unstructured":"Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120(5):1223\u20135","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8490_CR77","first-page":"38","volume":"80","author":"SB Forman","year":"2007","unstructured":"Forman SB, Garrett AB (2007) Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor. FcepsilonRI Cutis 80(1):38\u201340","journal-title":"FcepsilonRI Cutis"},{"issue":"2","key":"8490_CR78","first-page":"78","volume":"69","author":"C Incorvaia","year":"2008","unstructured":"Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG (2008) Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 69(2):78\u201380","journal-title":"Monaldi Arch Chest Dis"},{"issue":"5","key":"8490_CR79","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","volume":"29","author":"LE Sheinkopf","year":"2008","unstructured":"Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530\u20137","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"8490_CR80","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1398-9995.2009.02153.x","volume":"65","author":"C Caruso","year":"2010","unstructured":"Caruso C, Gaeta F, Valluzzi RL, Romano A (2010) Omalizumab efficacy in a girl with atopic eczema. Allergy 65(2):278\u20139","journal-title":"Allergy"},{"issue":"3","key":"8490_CR81","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5021\/ad.2010.22.3.349","volume":"22","author":"SY Park","year":"2010","unstructured":"Park SY, Choi MR, Na JI, Youn SW, Park KC, Huh CH (2010) Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 22(3):349\u201352","journal-title":"Ann Dermatol"},{"issue":"4","key":"8490_CR82","first-page":"357","volume":"29","author":"S Thaiwat","year":"2011","unstructured":"Thaiwat S, Sangasapaviliya A (2011) Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol 29(4):357\u201360","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"5","key":"8490_CR83","first-page":"416","volume":"21","author":"ME Ramirez del Pozo","year":"2011","unstructured":"Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, Gomez VJ (2011) Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 21(5):416\u20137","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"8490_CR84","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ad.2011.07.013","volume":"103","author":"MC Fernandez-Anton Martinez","year":"2012","unstructured":"Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez FR (2012) Omalizumab for the treatment of atopic dermatitis. Actas Dermo-sifilio Graficas 103(7):624\u20138","journal-title":"Actas Dermo-sifilio Graficas"},{"issue":"3","key":"8490_CR85","first-page":"190","volume":"23","author":"S Sanchez-Ramon","year":"2013","unstructured":"Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23(3):190\u20136","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"8490_CR86","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2230.2012.04438.x","volume":"38","author":"DH Kim","year":"2013","unstructured":"Kim DH, Park KY, Kim BJ, Kim MN, Mun SK (2013) Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38(5):496\u2013500","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"8490_CR87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","volume":"162","author":"SR Iyengar","year":"2013","unstructured":"Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89\u201393","journal-title":"Int Arch Allergy Immunol"},{"issue":"10","key":"8490_CR88","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1468-3083.2011.04326.x","volume":"26","author":"F Toledo","year":"2012","unstructured":"Toledo F, Silvestre JF, Munoz C (2012) Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis report of four cases. J Eur Acad Dermatol Venereol 26(10):1325\u20137","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"8490_CR89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","volume":"69","author":"M Hotze","year":"2014","unstructured":"Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R et al (2014) Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69(1):132\u20135","journal-title":"Allergy"},{"issue":"8","key":"8490_CR90","first-page":"629","volume":"16","author":"KA Fairman","year":"2010","unstructured":"Fairman KA, Curtiss FR (2010) Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm JMCP 16(8):629\u201339","journal-title":"J Manag Care Pharm JMCP"},{"issue":"1\u20133","key":"8490_CR91","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12026-014-8547-7","volume":"59","author":"KA Messingham","year":"2014","unstructured":"Messingham KA, Holahan HM, Fairley JA (2014) Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res 59(1\u20133):273\u20138","journal-title":"Immunol Res"},{"issue":"3","key":"8490_CR92","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","volume":"123","author":"JA Fairley","year":"2009","unstructured":"Fairley JA, Baum CL, Brandt DS, Messingham KA (2009) Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 123(3):704\u20135","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"8490_CR93","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","volume":"148","author":"VA London","year":"2012","unstructured":"London VA, Kim GH, Fairley JA, Woodley DT (2012) Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 148(11):1241\u20133","journal-title":"Arch Dermatol"},{"issue":"5","key":"8490_CR94","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","volume":"166","author":"C Dufour","year":"2012","unstructured":"Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D et al (2012) Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 166(5):1140\u20132","journal-title":"Br J Dermatol"},{"issue":"3","key":"8490_CR95","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71(3):468\u201374","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8490_CR96","first-page":"523","volume":"60","author":"AD Yalcin","year":"2014","unstructured":"Yalcin AD, Genc GE, Celik B, Gumuslu S (2014) Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab 60(3):523\u20134","journal-title":"Clin Lab"},{"issue":"4","key":"8490_CR97","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anl.2013.12.006","volume":"41","author":"M Nonaka","year":"2014","unstructured":"Nonaka M, Sakitani E, Yoshihara T (2014) Anti-IgE therapy to Kimura\u2019s disease: a pilot study. Auris Nasus Larynx 41(4):384\u20138","journal-title":"Auris Nasus Larynx"},{"key":"8490_CR98","doi-asserted-by":"crossref","unstructured":"Centers for medicare & medicaid services: off-label use of colorectal cancer drugs allowed in select clinical trials. Journal of oncology practice \/ American Society of Clinical Oncology. (2005)1(1):12\u20134","DOI":"10.1200\/JOP.1.1.12"},{"issue":"4","key":"8490_CR99","first-page":"233","volume":"27","author":"L Chularojanamontri","year":"2009","unstructured":"Chularojanamontri L, Wimoolchart S, Tuchinda P, Kulthanan K, Kiewjoy N (2009) Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 27(4):233\u20136","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1","key":"8490_CR100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.aller.2012.11.001","volume":"42","author":"M Rodriguez-Rodriguez","year":"2014","unstructured":"Rodriguez-Rodriguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Alvarez-Mon M (2014) Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immun (Madr) 42(1):78\u201380","journal-title":"Allergol Immun (Madr)"},{"issue":"1","key":"8490_CR101","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1398-9995.2009.02188.x","volume":"65","author":"C Bindslev-Jensen","year":"2010","unstructured":"Bindslev-Jensen C, Skov PS (2010) Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 65(1):138\u20139","journal-title":"Allergy"},{"issue":"3","key":"8490_CR102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2332\/allergolint.14-LE-0699","volume":"63","author":"AB Ozturk","year":"2014","unstructured":"Ozturk AB, Kocaturk E, Ozturk E (2014) Successful treatment of a bullous urticaria with omalizumab. Allergol Int 63(3):495\u20137","journal-title":"Allergol Int"},{"issue":"2","key":"8490_CR103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2230.2012.04430.x","volume":"38","author":"A Pressler","year":"2013","unstructured":"Pressler A, Grosber M, Halle M, Ring J, Brockow K (2013) Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol 38(2):151\u20133","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"8490_CR104","first-page":"287","volume":"23","author":"P Mur Gimeno","year":"2013","unstructured":"Mur Gimeno P, Martin Iglesias A, Lombardero Vega M, Bautista Martinez P, Ventura LP (2013) Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol 23(4):287\u20138","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"8490_CR105","first-page":"519","volume":"23","author":"F Carballada","year":"2013","unstructured":"Carballada F, Nunez R, Martin-Lazaro J, Juarez Y, Castineira I, Fernandez L et al (2013) Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol 23(7):519\u201321","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"7","key":"8490_CR106","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1398-9995.2009.02268.x","volume":"65","author":"U Bullerkotte","year":"2010","unstructured":"Bullerkotte U, Wieczorek D, Kapp A, Wedi B (2010) Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 65(7):931\u20132","journal-title":"Allergy"},{"issue":"6","key":"8490_CR107","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0781.2011.00624.x","volume":"27","author":"G Duchini","year":"2011","unstructured":"Duchini G, Baumler W, Bircher AJ, Scherer K (2011) Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 27(6):336\u20137","journal-title":"Photodermatol. Photoimmunol. Photomed"},{"issue":"11","key":"8490_CR108","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1398-9995.2008.01879.x","volume":"63","author":"O Guzelbey","year":"2008","unstructured":"Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M (2008) Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 63(11):1563\u20135","journal-title":"Allergy"},{"issue":"4","key":"8490_CR109","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaci.2007.07.041","volume":"120","author":"MF Sands","year":"2007","unstructured":"Sands MF, Blume JW, Schwartz SA (2007) Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 120(4):979\u201381","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8490_CR110","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaci.2013.12.1089","volume":"133","author":"D Larenas-Linnemann","year":"2014","unstructured":"Larenas-Linnemann D, Wahn U, Kopp M (2014) Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 133(3):937\u2013e2","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8490_CR111","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","volume":"117","author":"TB Casale","year":"2006","unstructured":"Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134\u201340","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8490_CR112","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5114\/pdia.2014.43192","volume":"31","author":"I Stelmach","year":"2014","unstructured":"Stelmach I, Sztafinska A, Woicka-Kolejwa K, Jerzynska J (2014) Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report. Postepy dermatologii i alergologii 31(3):191\u20133","journal-title":"Postepy dermatologii i alergologii"},{"issue":"2","key":"8490_CR113","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","volume":"125","author":"M Massanari","year":"2010","unstructured":"Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125(2):383\u20139","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8490_CR114","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jaci.2010.06.014","volume":"126","author":"HM Tartibi","year":"2010","unstructured":"Tartibi HM, Majmundar AR, Khan DA (2010) Successful use of omalizumab for prevention of fire ant anaphylaxis. J Allergy Clin Immunol 126(3):664\u20135","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8490_CR115","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.anai.2014.08.007","volume":"113","author":"KS Tille","year":"2014","unstructured":"Tille KS, Parker AL (2014) Imported fire ant rush desensitization using omalizumab and a premedication regimen. Ann Allergy Asthma Immunol 113(5):574\u20136","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"8490_CR116","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00105-014-2778-3","volume":"65","author":"D Wieczorek","year":"2014","unstructured":"Wieczorek D, Kapp A, Wedi B (2014) Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab. Hautarzt 65(9):791\u20135, Unvertraglichkeit der spezifischen Immuntherapie mit Hymenopterengift: Mit Omalizumab die Hurde nehmen","journal-title":"Hautarzt"},{"issue":"11","key":"8490_CR117","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","volume":"348","author":"DY Leung","year":"2003","unstructured":"Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348(11):986\u201393","journal-title":"N Engl J Med"},{"issue":"5","key":"8490_CR118","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","volume":"127","author":"HA Sampson","year":"2011","unstructured":"Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM et al (2011) A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127(5):1309\u201310","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8490_CR119","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","volume":"132","author":"LC Schneider","year":"2013","unstructured":"Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132(6):1368\u201374","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8490_CR120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","volume":"130","author":"JH Savage","year":"2012","unstructured":"Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA (2012) Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 130(5):1123\u20139","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8490_CR121","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","volume":"127","author":"KC Nadeau","year":"2011","unstructured":"Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow\u2019s milk allergy. J Allergy Clin Immunol 127(6):1622\u20134","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8490_CR122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","volume":"10","author":"P Begin","year":"2014","unstructured":"Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B et al (2014) Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 10(1):7","journal-title":"Allergy Asthma Clin Immunol"},{"key":"8490_CR123","doi-asserted-by":"crossref","unstructured":"Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. (2014) Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol","DOI":"10.1111\/pai.12259"},{"issue":"2","key":"8490_CR124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40521-014-0015-z","volume":"1","author":"M Manohar","year":"2014","unstructured":"Manohar M, Nadeau KC (2014) The potential of anti-IgE in food allergy therapy. Curr Treat Options Allergy 1(2):145\u201356","journal-title":"Curr Treat Options Allergy"},{"issue":"11","key":"8490_CR125","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","volume":"170","author":"R Rocha","year":"2011","unstructured":"Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J et al (2011) Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170(11):1471\u20134","journal-title":"Eur J Pediatr"},{"key":"8490_CR126","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0065-2776(05)89005-4","volume":"89","author":"J Robyn","year":"2006","unstructured":"Robyn J, Metcalfe DD (2006) Systemic mastocytosis. Adv Immunol 89:169\u2013243","journal-title":"Adv Immunol"},{"issue":"3","key":"8490_CR127","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","volume":"63","author":"K Kontou-Fili","year":"2008","unstructured":"Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63(3):376\u20138","journal-title":"Allergy"},{"issue":"3","key":"8490_CR128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","volume":"2","author":"KC Sokol","year":"2014","unstructured":"Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Prac 2(3):266\u201370","journal-title":"J Allergy Clin Immunol Prac"},{"issue":"6","key":"8490_CR129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2013.07.004","volume":"1","author":"EN Silva da","year":"2013","unstructured":"da Silva EN, Randall KL (2013) Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Prac 1(6):687\u20138","journal-title":"J Allergy Clin Immunol Prac"},{"issue":"7","key":"8490_CR130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","volume":"65","author":"JA Douglass","year":"2010","unstructured":"Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O\u2019Hehir RE (2010) Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 65(7):926\u20137","journal-title":"Allergy"},{"issue":"1","key":"8490_CR131","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","volume":"113","author":"A Jagdis","year":"2014","unstructured":"Jagdis A, Vadas P (2014) Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol 113(1):115\u20136","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"8490_CR132","first-page":"52","volume":"45","author":"G Paraskevopoulos","year":"2013","unstructured":"Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D (2013) Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol 45(2):52\u20135","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"5","key":"8490_CR133","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","volume":"111","author":"A Matito","year":"2013","unstructured":"Matito A, Blazquez-Goni C, Morgado JM, Alvarez-Twose I, Mollejo M, Sanchez-Munoz L et al (2013) Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 111(5):425\u20136","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"8490_CR134","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2012.02.021","volume":"108","author":"MC Bell","year":"2012","unstructured":"Bell MC, Jackson DJ (2012) Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 108(5):383\u20134","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"8490_CR135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","volume":"94","author":"L Kibsgaard","year":"2014","unstructured":"Kibsgaard L, Skjold T, Deleuran M, Vestergaard C (2014) Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol 94(3):363\u20134","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"8490_CR136","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","volume":"120","author":"F Siebenhaar","year":"2007","unstructured":"Siebenhaar F, Kuhn W, Zuberbier T, Maurer M (2007) Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120(1):213\u20135","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8490_CR137","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","volume":"119","author":"MC Carter","year":"2007","unstructured":"Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119(6):1550\u20131","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8490_CR138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.anai.2012.07.021","volume":"109","author":"SM Bray","year":"2012","unstructured":"Bray SM, Fajt ML, Petrov AA (2012) Successful treatment of exercise-induced anaphylaxis with omalizumab. Ann Allergy Asthma Immunol 109(4):281\u20132","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"8490_CR139","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5415\/apallergy.2014.4.2.126","volume":"4","author":"J Lee","year":"2014","unstructured":"Lee J (2014) Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy. Asia Pacific allergy 4(2):126\u20138","journal-title":"Asia Pacific allergy"},{"issue":"6","key":"8490_CR140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1346-8138.2012.01520.x","volume":"39","author":"M Demirturk","year":"2012","unstructured":"Demirturk M, Gelincik A, Colakoglu B, Dal M, Buyukozturk S (2012) Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 39(6):552\u20134","journal-title":"J Dermatol"},{"issue":"5","key":"8490_CR141","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1081-1206(10)60296-7","volume":"101","author":"JD Jones","year":"2008","unstructured":"Jones JD, Marney SR Jr, Fahrenholz JM (2008) Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 101(5):550\u20131","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"8490_CR142","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","volume":"111","author":"MP Berges-Gimeno","year":"2003","unstructured":"Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111(1):180\u20136","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8490_CR143","first-page":"448","volume":"20","author":"I Bobolea","year":"2010","unstructured":"Bobolea I, Barranco P, Fiandor A, Cabanas R, Quirce S (2010) Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 20(5):448\u20139","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"8490_CR144","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.aller.2012.02.005","volume":"41","author":"K Aksu","year":"2013","unstructured":"Aksu K, Kurt E (2013) Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 41(3):208\u201310","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"8490_CR145","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/27.4.376692","volume":"27","author":"Z Vogel","year":"1979","unstructured":"Vogel Z, Towbin M, Daniels MP (1979) Alpha-bungarotoxin-horseradish peroxidase conjugate: preparation, properties and utilization for the histochemical detection of acetylcholine receptors. J Histochem Cytochem 27(4):846\u201351","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"8490_CR146","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2007.07.037","volume":"120","author":"V Matheu","year":"2007","unstructured":"Matheu V, Franco A, Perez E, Hernandez M, Barrios Y (2007) Omalizumab for drug allergy. J Allergy Clin Immunol 120(6):1471\u20132, author reply 2\u20133","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8490_CR147","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.2337\/dc12-0115","volume":"35","author":"C Cavelti-Weder","year":"2012","unstructured":"Cavelti-Weder C, Muggli B, Keller C, Babians-Brunner A, Biason-Lauber A, Donath MY et al (2012) Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care 35(6):e41","journal-title":"Diabetes Care"},{"issue":"10","key":"8490_CR148","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc0808282","volume":"360","author":"PF Yong","year":"2009","unstructured":"Yong PF, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MA et al (2009) Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 360(10):1045\u20137","journal-title":"N Engl J Med"},{"issue":"1","key":"8490_CR149","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaip.2013.08.009","volume":"2","author":"S Ojaimi","year":"2014","unstructured":"Ojaimi S, Harnett PR, Fulcher DA (2014) Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Prac 2(1):105\u20136","journal-title":"J Allergy Clin Immunol Prac"},{"issue":"5","key":"8490_CR150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0034-1368335","volume":"231","author":"C Heinz","year":"2014","unstructured":"Heinz C, Heiligenhaus A (2014) Vernal keratoconjunctivitis. Klin Monbl Augenheilkd 231(5):505\u201311, Keratoconjunctivitis vernalis","journal-title":"Klin Monbl Augenheilkd"},{"issue":"4","key":"8490_CR151","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/pai.12197","volume":"25","author":"P Vichyanond","year":"2014","unstructured":"Vichyanond P, Pacharn P, Pleyer U, Leonardi A (2014) Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol 25(4):314\u201322","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"8490_CR152","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","volume":"40","author":"J Sanchez","year":"2012","unstructured":"Sanchez J, Omalizumab CR (2012) An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr) 40(5):319\u201320","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"8490_CR153","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","volume":"17","author":"TA Klerk de","year":"2013","unstructured":"de Klerk TA, Sharma V, Arkwright PD, Biswas S (2013) Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS Off Pub Am Assoc Ped Ophthalmol Strabismus Am Assoc Ped Ophthalmol Strabismus 17(3):305\u20136","journal-title":"J AAPOS Off Pub Am Assoc Ped Ophthalmol Strabismus Am Assoc Ped Ophthalmol Strabismus"},{"issue":"8","key":"8490_CR154","first-page":"712","volume":"67","author":"S Matsutani","year":"1995","unstructured":"Matsutani S, Kobayashi T, Kousaka T (1995) Eosinophilic otitis media. Otolaryngol Head Neck Surg 67(8):712\u20133","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"9","key":"8490_CR155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5631\/jibirin.100.715","volume":"100","author":"T Kawano","year":"2007","unstructured":"Kawano T, Ishitoya J, Tsukuda M (2007) Sinusitis with eosinophilic otitis media. Practica Oto-Rhino-Laryngologica 100(9):715\u201324","journal-title":"Practica Oto-Rhino-Laryngologica"},{"key":"8490_CR156","first-page":"340525","volume":"2012","author":"A Okude","year":"2012","unstructured":"Okude A, Tagaya E, Kondo M, Nonaka M, Tamaoki J (2012) A case of severe asthma with eosinophilic otitis media successfully treated with anti-IgE monoclonal antibody omalizumab. Case Rep Pulmonol 2012:340525","journal-title":"Case Rep Pulmonol"},{"issue":"7","key":"8490_CR157","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MAO.0b013e318263d5b8","volume":"33","author":"Y Iino","year":"2012","unstructured":"Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2012) Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otology Neurotol Off Publ Am Otolog Soc Am Neurotol Soc [and] Eur Acad Otolog Neurotol 33(7):1218\u201324","journal-title":"Otology Neurotol Off Publ Am Otolog Soc Am Neurotol Soc [and] Eur Acad Otolog Neurotol"},{"issue":"4","key":"8490_CR158","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/00016489.2013.868601","volume":"134","author":"Y Iino","year":"2014","unstructured":"Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2014) Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol 134(4):366\u201372","journal-title":"Acta Otolaryngol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8490-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-015-8490-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-015-8490-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:23:13Z","timestamp":1599099793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-015-8490-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,6]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["8490"],"URL":"https:\/\/doi.org\/10.1007\/s12016-015-8490-y","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,6]]}}}